Pfizer Inc. (NYSE:PFE) Working with VLST over Cancer Immune Drug.
Pfizer Inc. (NASDAQ:PFE) will work with privately held biotechnology firm VLST Corp. on a possible immune treatment for cancer.
VLST reported on Friday that it intends to begin testing the drug, named CP-870,893, as a cure for cancer in mid-stage clinical trials. The Seattle firm has carried out initial-stage trials of the drug and stated that it lately received $5 million in financing to facilitate funding mid-stage studies.
Pfizer and VLST will share the rights to develop and market the drug as a “cancer vaccine,” or a therapy that is designed to stimulate the immune system to fight cancer.
One of the most critical factors in measuring the performance of a company is its Return on Assets ratio, which is an indicator of how profitable a company is relative to its total assets. Pfizer Inc. (NYSE:PFE) recently had ROA ratio of 4.67% while its market capitalization was 178.22 billion.
Previous month, PFE Inc stock price volatility was 1.05%. In its share capital PFE has 7.47 billion outstanding shares and 7.47 billion shares have been floated in the market exchange. PFE stock institutional ownership remained 72.08% while insider ownership included 0.05%.
The stock is ahead of its 52week low +45.57% and is lagging behind from its 52 week high price -2.09%. Company’s beta coefficient included 0.70. Beta factor evaluates the amount of market risk associated with market trade.
PFE stock traded with a starting price of $23.88 and throughout the trading session climbed to a high of $24.07 and later, when day-trade ended, the stock finally surged +0.08% to $23.86 with a relative volume of 26.23 million shares.
Its competitor, Merck & Co., Inc. (NYSE:MRK) shares opened the session at $43.33 slipped -0.16% and settled at $43.05 with a relative trading volume of 27.58 million shares and Novartis AG (ADR) (NYSE:NVS) shares opened the session at $59.32 edged up 0.44% and settled at $59.01 with a relative trading volume of 1.41 million shares.